samedan logo

 
 
spacer
home > ebr > winter 2003 > cordia-europabio convention 2003
PUBLICATIONS
European Biopharmaceutical Review

CORDIA-EuropaBio Convention 2003

Europe's first true biotechnology convention got off the ground in style in Vienna during the first week of December 2003. Approximately 1,300 delegates from 37 countries attended the Convention, which featured six plenary sessions, 60 conference panel sessions (across health care, industrial and agri-food biotechnology), six workshops, 10 different therapeutic/technology partnering sessions and an international exhibition with a range of companies from across the world.

The conference programme launched directly into the key issues that the European sector faces with the Opening Plenary featuring representation from all stakeholders in the future development of the European biotechnology industry - political, scientific, patient, mainstream industry and SMEs. The EU's Lisbon Summit objective to become the leading knowledge-based economy by 2010 is clearly not realisable on present performance. Even worse, the gap between Europe and North America is widening with Mrs Mary Harney, Deputy Prime Minister of Ireland and incoming President of the EU Competitiveness Council quoting that whilst the US is currently on average "30 per cent richer than Europe", it will be "50 per cent richer by the year 2050" if things continue as they are.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Review by Dr Helen Abbott, Editor of EBR
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck to Provide BioReliance® End-to-End Solutions to Phanes Therapeutics

• Collaboration to accelerate development and manufacturing of Bispecific Antibody • Merck plans to offer Phanes a full suite of products and services under its BioReliance® offering
More info >>

White Papers

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

Clinical Ink

Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

23-26 March 2020, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 23 – 26 March 2020. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement